Logistics of Monitoring of Vitamin K Antagonists in Western European Countries: Prefer in Vte Registry

Manuel Monreal; Rupert Bauersachs; Anselm K. Gitt; Petra Laeis; Patrick Mismetti; SN Willich; Alexander T. Cohen; Giancarlo Agnelli

doi:10.1016/j.jval.2014.08.1526

Related publications

Article2014

C0473: Prevention of Thromboembolic Events? European Registry in Venous Thromboembolism - Design of the Prefer in VTE

A. Cohen, Rupert Bauersachs, A. K. Gitt, Petra Laeis, Patrick Mismetti, M. Monreal, Stefan N. Willich, Giancarlo Agnelli

Article2014

Readmittance To Hospital Within 6 Months After A Venous Thromboembolism Event: Prefer In Vte Registry

Rupert Bauersachs, A. K. Gitt, Patrick Mismetti, Manuel Monreal, SN Willich, Will Wolf, Giancarlo Agnelli, A. Cohen

Article2014

Treatment Satisfaction In Patients With Venous Thromboembolism As Measured With Pact-Q2: Prefer In Vte Registry

SN Willich, Rupert Bauersachs, Anselm K. Gitt, Patrick Mismetti, Manuel Monreal, Will Wolf, Giancarlo Agnelli, Alexander T. Cohen

Article2022

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Professor Gregory Lip, Agnieszka Kotalczyk, Christine Teutsch, Hans‐Christoph Diener, Sérgio Dubner, Jonathan L. Halperin, Changsheng Ma, Kenneth J. Rothman, Sabrina Marler, Venkatesh Kumar Gurusamy, Menno V. Huisman, Dzifa Wosornu Abban, Emad F. Aziz, Marica Bracic Kalan, Nasser Abdul, Luciano Marcelo Backes, Drew Bradman, Atilio Marcelo Abud, Erik Badings, Donald Brautigam, Fran Adams, Ermentina Bagni,

Article2017

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry

Rupert Bauersachs, Giancarlo Agnelli, Anselm K. Gitt, Manuel Monréal, Patrick Mismetti, Stefan N. Willich, Petra Laeis, Eva‐Maria Fronk, Peter Bramlage, Alexander T. Cohen

Logistics of Monitoring of Vitamin K Antagonists in Western European Countries: Prefer in Vte Registry

Discussion(0)

Related publications

C0473: Prevention of Thromboembolic Events? European Registry in Venous Thromboembolism - Design of the Prefer in VTE

Readmittance To Hospital Within 6 Months After A Venous Thromboembolism Event: Prefer In Vte Registry

Treatment Satisfaction In Patients With Venous Thromboembolism As Measured With Pact-Q2: Prefer In Vte Registry

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry